retatrutide ly3437943 triple agonist glp-1 gip glucagon Retatrutide: How GLP-1/GIP/Glucagon Receptor Agonism Differs From Existing Compounds LY3437943, a novel triple GIP,

How many people take GLP-1 medications

The glucagon-like peptide-1 receptor agonist (GLP-1) liraglutide may protect the brains of people with mild Alzheimers disease (AD) and reduce cognit

Credits: istock.org

Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk

Medicare has never paid for weight-loss drugs at scale

95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)